| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| AMGN | Amgen Inc. | $200.81 | $129.98B | N/A |
5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates
http://www.zacks.com/stock/news/256560/5-major-drug-stocks-likely-to-beat-q1-earnings-estimates?cid=CS-ZC-FT-256560
Apr 17, 2017 - 2017 is expected to be a strong year for drug stocks.
0
AbbVie Inc.: The Bear Case From a Bull
https://www.fool.com/investing/2017/04/14/abbvie-inc-the-bear-case-from-a-bull.aspx?source=iedfolrf0000001
Apr 14, 2017 - AbbVie has a lot of things going for it, but the biotech faces some major risks.
0
Mylan Down on FDA Warning Letter to Manufacturing Facility
http://www.zacks.com/stock/news/256244/mylan-down-on-fda-warning-letter-to-manufacturing-facility?cid=CS-ZC-FT-256244
Apr 12, 2017 - Shares of Mylan, Inc. (MYL) dropped 2% after the company received a warning letter from the FDA for its manufacturing facility in India
0
ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
http://www.zacks.com/stock/news/256054/anths-anth-blisibimod-completes-dosing-in-phase-iii-study?cid=CS-ZC-FT-256054
Apr 11, 2017 - Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN).
0
Kite Pharma Completes Filing for CAR-T Therapy with FDA
http://www.zacks.com/stock/news/254949/kite-pharma-completes-filing-for-car-t-therapy-with-fda?cid=CS-ZC-FT-254949
Apr 03, 2017 - Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.
0
Mylan Receives CRL for Generic Advair Diskus From the FDA
http://www.zacks.com/stock/news/254929/mylan-receives-crl-for-generic-advair-diskus-from-the-fda?cid=CS-ZC-FT-254929
Mar 31, 2017 - Mylan N.V. (MYL) recently suffered a huge setback when it received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus.
0
Amgen's Leukemia Drug Accepted for Priority Review by FDA
http://www.zacks.com/stock/news/254704/amgens-leukemia-drug-accepted-for-priority-review-by-fda?cid=CS-ZC-FT-254704
Mar 30, 2017 - Amgen Inc. (AMGN) recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA.
0
Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
http://www.zacks.com/stock/news/254462/biotech-stock-roundup-regeneron-tesaro-drugs-approved-vertex-scores-big-in-study?cid=CS-ZC-FT-254462
Mar 29, 2017 - Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.
0
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe
http://www.zacks.com/stock/news/254398/pfizers-arthritis-drug-xeljanz-gets-marketing-nod-in-europe?cid=CS-ZC-FT-254398
Mar 28, 2017 - Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.
0
The 'Fearless Girl' Statue Isn't a Symbol, It Is an Advertisement
http://www.zacks.com/stock/news/254260/the-fearless-girl-statue-isnt-a-symbol-it-is-an-advertisement?cid=CS-ZC-FT-254260
Mar 28, 2017 - The Fearless Girl statue has taken New York City by storm. However, this statue, which is facing down the Charging Bull, is actually an ad.
59